﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 08:52:36 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Athera elects new Chairman of the Board and moves to new premises</title><link>http://news.cision.com/athera-biotechnologies-ab/r/athera-elects-new-chairman-of-the-board-and-moves-to-new-premises,c9468932</link><guid isPermaLink="false">cision1432450</guid><description><![CDATA[STOCKHOLM, SWEDEN –Sept 19, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board. Earlier this year, Tomas Odergren, VP Clinical Development at Karolinska Development AB, joined the Board of Directors.
The extraordinary shareholders meeting in Athera has elected Gunnar Olsson new Chairman of the Board after Per Sjöberg, who has been leading the company for eight years. Dr Olsson joins Athera after 24 years in AstraZeneca, where he has]]></description><pubDate>Thu, 19 Sep 2013 06:00:00 GMT</pubDate></item><item><title>Athera and Medirista sign agreement to transfer the Annexin A5 project</title><link>http://news.cision.com/athera-biotechnologies-ab/r/athera-and-medirista-sign-agreement-to-transfer-the-annexin-a5-project,c9455408</link><guid isPermaLink="false">cision1408510</guid><description><![CDATA[STOCKHOLM, SWEDEN – Aug 23, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that the rights to the recombinant Annexin A5 have been transferred to Medirista AB. Medirista is a biotech company owned by the original innovators of the Annexin A5 project, Johan and Anna Frostegård. The whole patent portfolio together with key preclinical assets have been transferred. Athera will continue its focus on development of the lead product candidate, the fully human antibody in atherosclerosis.
Recombinant Annexin A5 has been developed to preclinical stage]]></description><pubDate>Fri, 23 Aug 2013 07:30:00 GMT</pubDate></item><item><title>Low levels of anti-PC predict vein graft failure</title><link>http://news.cision.com/athera-biotechnologies-ab/r/low-levels-of-anti-pc-predict-vein-graft-failure,c9324568</link><guid isPermaLink="false">cision1149965</guid><description><![CDATA[STOCKHOLM, SWEDEN – October 25, 2012. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that results from a new study were presented at the Pacific Northwest Vascular Society Annual Meeting in Vancouver, Canada. The data shows that low levels of plasma anti-PC, measured with Athera’s CVDefine® kit, are associated with a high risk for vein graft failure after bypass surgery.
It is known from previous published studies that low plasma levels of antibodies against phosphorylcholine (anti-PC) are linked to poor prognosis in acute heart attack patients, as]]></description><pubDate>Thu, 25 Oct 2012 11:00:31 GMT</pubDate></item></channel></rss>